Immatics N.V.
For the period ended Jun 1, 2026. Filed Jun 1, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Jun 1, 2026 · Filed Jun 1, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Next development steps:
Next development steps:
The clinical activity observed in ovarian cancer, a tumor type generally associated with lower levels of PRAME expression, together with the observed activity across tumor types with different and distinct tumor microenvironments, supports the broad applicability of IMA203CD8 across solid tumors with differing levels of PRAME and tumor biology, starting with ovarian and uterine cancer. Updated data from the ongoing study, including durability follow-up at the RP2D, are planned for presentation in the second half of 2026. Immatics is expanding clinical evaluation of IMA203CD8 into additional PRAME-positive solid tumor indications to more fully assess its therapeutic potential.
Highlights of Immatics’ clinical data on IMA203CD8 presented at ASCO 2026
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.